Genitourinary Cancer

Top Story

Risk calculator an accurate, cost-effective prescreening tool for PTEN mutations

July 30, 2015

The PTEN Cleveland Clinic score appeared to be a cost-effective prescreening tool to identify patients with Cowden-like disease who are appropriate candidates for PTEN germline mutation testing, according to study findings.

Twenty-five percent of patients with Cowden syndrome harbor pathogenic germline PTEN mutations, which increase the risk for breast, thyroid, uterine, renal and other cancers, according to study background. However, physicians can be challenged to identify patients with Cowden-like disease who are appropriate for PTEN testing.

FDA News

FDA grants breakthrough drug designation to Lenvima for advanced RCC

July 29, 2015
The FDA granted breakthrough drug designation to lenvatinib for the treatment of patients with advanced or metastatic renal cell carcinoma who received prior treatment…
FDA News

FDA grants breakthrough therapy designation to Azedra for pheochromocytoma, paraganglioma

July 28, 2015
The FDA granted breakthrough therapy designation to Ultratrace iobenguane I-131 for the treatment of patients with iobenguane-avid metastatic or recurrent…
Assiamira Ferrera In the Journals

Bladder cancer risk not increased with pioglitazone therapy

July 21, 2015
Through an analysis of nearly 200,000 patients, no statistically significant increased risk for bladder cancer was found with the use of Actos, according to recent study…
CME
Hematology Oncology Case Consults

The Patient with Melanoma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with melanoma.
More »
Meeting News Coverage Video
Recurrent themes of ASCO: Money and molecules

Recurrent themes of ASCO: Money and molecules

June 7, 2013
CHICAGO — Donald L. Trump, MD, FACP, president and CEO of Roswell Park Cancer Institute, offers his insights on…
More »
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
Charis Eng, MD, PhD In the Journals

Risk calculator an accurate, cost-effective prescreening tool for PTEN mutations

July 30, 2015
The PTEN Cleveland Clinic score appeared to be a cost-effective prescreening tool to identify patients with Cowden-like disease who are appropriate…
FDA News

FDA grants breakthrough drug designation to Lenvima for advanced RCC

July 29, 2015
The FDA granted breakthrough drug designation to lenvatinib for the treatment of patients with advanced or metastatic renal cell carcinoma who…
FDA News

FDA grants breakthrough therapy designation to Azedra for pheochromocytoma, paraganglioma

July 28, 2015
The FDA granted breakthrough therapy designation to Ultratrace iobenguane I-131 for the treatment of patients with iobenguane-avid metastatic or…
Assiamira Ferrera In the Journals

Bladder cancer risk not increased with pioglitazone therapy

July 21, 2015
Through an analysis of nearly 200,000 patients, no statistically significant increased risk for bladder cancer was found with the use of Actos…

What are symptoms of cancer in children?

July 17, 2015
Cancer is a difficult disease to detect in children, as symptoms may be minimal or even nonexistent.Cancer is the second leading cause of death among…

What are testicular cancer symptoms?

July 16, 2015
Testicular cancer is a type of cancer that occurs in the testicles, two egg-shaped organs located inside the scrotum.The testicles play an important…
Petros Grivas, MD, PhD Meeting News Coverage

Top Takeaways from ASCO: Urothelial Cancer

July 1, 2015
CHICAGO — Data on two immune checkpoint inhibitors for the treatment of urothelial cancer represent important findings for this type of cancer…
Association News

Urological society presents Distinguished Service Award

June 20, 2015
The Chicago Urological Society presented its Distinguished Service Award to Robert Flanigan, MD, chair of the department of urology at Loyola…
Meeting News Coverage

Pembrolizumab shows promise for advanced bladder cancer

June 19, 2015
CHICAGO — Pembrolizumab demonstrated encouraging antitumor activity and OS rates in patients with advanced urothelial cancer, according to…
Rini Brian In the Journals

Gene assay predicts recurrence following nephrectomy in renal cell carcinoma

June 18, 2015
Recurrence scores based on a 16-gene assay accurately predicted clinical outcomes in patients with surgically treated clear cell renal cell…
More Headlines »